Search - tctmd.com

Displaying 961 - 980 of 1360

Sort: Relevancy | Date

News Daily News

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

Todd Neale

October 26, 2015

$Bivalirudin Versus Unfractionated Heparin Analysis: What Is Really Best in Which Patients?$

Presentation TCT 2015

Bivalirudin Versus Unfractionated Heparin Analysis: What Is Really Best in Which Patients?

Presenter: Carlo Briguori, Roxana Mehran, Carey D. Kimmelstiel

October 15, 2015

Presentation TCT 2015

MATRIX Trial Recap: Interaction Between Access Site and Antithrombin Choice in ACS

Presenter: Carlo Briguori, Roxana Mehran

October 15, 2015

Presentation TCT 2015

The REG1 Anticoagulation System: Lessons From Factor IX Inhibitor Using RNA Aptamer Technology

Presenter: Carlo Briguori, Roxana Mehran

October 15, 2015

News Industry News

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

October 15, 2015

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

Presentation TCT 2015

Alternatives to Anticoagulation: Left Atrial Appendage Occlusion Devices

Presenter: Gerhard C. Schuler, Matthew J. Price

October 14, 2015

Presentation TCT 2015

Data Gaps and Future Trial Pathways: Possible Study Designs for New Devices, Anticoagulation Ineligible Patients, and Comparative NOAC Data

Presenter: Nicole Ibrahim, Saibal Kar, Zoltan G. Turi

October 14, 2015

News Conference News TCT 2015

Manual Thrombectomy Does Not Improve Outcomes in High-Risk STEMI Patients

October 14, 2015

Presentation TCT 2015

TCT 77: Risk and Benefits of Triple Therapy in Patients Undergoing Percutaneous Coronary Stent Implantation Requiring Chronic Oral Anticoagulation A Meta-analysis of 12 Trials

Presenter: Lisa K. Jennings, Neal S. Kleiman, Lucia Barbieri

October 13, 2015

Presentation TCT 2015

PCI and Atrial Fibrillation Anticoagulation: Triple or Dual Therapy?

Presenter: George D. Dangas, Paul A. Gurbel, C. Michael Gibson

October 13, 2015

Presentation TCT 2015

Anticoagulation in the Periimplant Period (Pre, Peri, and Post): An Evidence-Based Analysis

Presenter: Maurice Buchbinder, Brian K. Whisenant, Sameer Gafoor

October 12, 2015

Presentation TCT 2015

The Clinical Impact of Stroke With 2 Preventative Strategies: LAA Closure vs Chronic Oral Anticoagulation

Presenter: Reda Ibrahim, Matthew J. Price, Vivek Y. Reddy

October 11, 2015

Presentation TCT 2015

Debate: Is LAA Closure an Alternative to Oral Anticoagulation in Low Bleeding Risk Patients? Yes, LAA Closure Is at Least as Good as Oral Anticoagulation!

Presenter: Reda Ibrahim, Matthew J. Price, Saibal Kar

October 11, 2015

Presentation TCT 2015

Debate: Is LAA Closure an Alternative to Oral Anticoagulation in Low Bleeding Risk Patients? No, It Should Be Limited to Anticoagulation Contraindicated Patients!

Presenter: Reda Ibrahim, Matthew J. Price, Jai-Wun Park

October 11, 2015

Presentation TCT 2015

Shades of Gray? Defining the Range of Patients Contraindicated for Anticoagulation

Presenter: David R. Holmes Jr., Vivek Y. Reddy, Piera Capranzano

October 11, 2015

Presentation TCT 2015

Weighing the Risk of Stroke in Atrial Fibrillation vs the Risk of Bleeding on Anticoagulation

Presenter: David R. Holmes Jr., Vivek Y. Reddy, Neal S. Kleiman

October 11, 2015

News Conference News TCT 2015

Use of LAA Occlusion in Low-Risk Patients Debated

Todd Neale

October 11, 2015

News Conference News TCT 2015

Cath Lab Economics: Pursuit of a Light at the End of the Tunnel

Nicole Lou

October 11, 2015

News Industry News

Scripps experts present at 2015 TCT scientific symposium

October 09, 2015

Advertisement

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

Bivalirudin Versus Unfractionated Heparin Analysis: What Is Really Best in Which Patients?

MATRIX Trial Recap: Interaction Between Access Site and Antithrombin Choice in ACS

The REG1 Anticoagulation System: Lessons From Factor IX Inhibitor Using RNA Aptamer Technology

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Alternatives to Anticoagulation: Left Atrial Appendage Occlusion Devices

Data Gaps and Future Trial Pathways: Possible Study Designs for New Devices, Anticoagulation Ineligible Patients, and Comparative NOAC Data

Manual Thrombectomy Does Not Improve Outcomes in High-Risk STEMI Patients

TCT 77: Risk and Benefits of Triple Therapy in Patients Undergoing Percutaneous Coronary Stent Implantation Requiring Chronic Oral Anticoagulation A Meta-analysis of 12 Trials

PCI and Atrial Fibrillation Anticoagulation: Triple or Dual Therapy?

Anticoagulation in the Periimplant Period (Pre, Peri, and Post): An Evidence-Based Analysis

The Clinical Impact of Stroke With 2 Preventative Strategies: LAA Closure vs Chronic Oral Anticoagulation

Debate: Is LAA Closure an Alternative to Oral Anticoagulation in Low Bleeding Risk Patients? Yes, LAA Closure Is at Least as Good as Oral Anticoagulation!

Debate: Is LAA Closure an Alternative to Oral Anticoagulation in Low Bleeding Risk Patients? No, It Should Be Limited to Anticoagulation Contraindicated Patients!

Shades of Gray? Defining the Range of Patients Contraindicated for Anticoagulation

Weighing the Risk of Stroke in Atrial Fibrillation vs the Risk of Bleeding on Anticoagulation

Use of LAA Occlusion in Low-Risk Patients Debated

Cath Lab Economics: Pursuit of a Light at the End of the Tunnel

Scripps experts present at 2015 TCT scientific symposium

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content